0001209191-18-052300.txt : 20180926
0001209191-18-052300.hdr.sgml : 20180926
20180926164829
ACCESSION NUMBER: 0001209191-18-052300
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20180926
FILED AS OF DATE: 20180926
DATE AS OF CHANGE: 20180926
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Haag-Molkenteller Cornelia
CENTRAL INDEX KEY: 0001748297
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38667
FILM NUMBER: 181088404
MAIL ADDRESS:
STREET 1: C/O UROVANT SCIENCES, INC.
STREET 2: 5151 CALIFORNIA AVENUE, SUITE 250
CITY: IRVINE
STATE: CA
ZIP: 92617
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Urovant Sciences Ltd.
CENTRAL INDEX KEY: 0001740547
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D0
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 5151 CALIFORNIA AVENUE
STREET 2: SUITE 250
CITY: IRVINE
STATE: CA
ZIP: 92617
BUSINESS PHONE: 949-226-6029
MAIL ADDRESS:
STREET 1: 5151 CALIFORNIA AVENUE
STREET 2: SUITE 250
CITY: IRVINE
STATE: CA
ZIP: 92617
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2018-09-26
0
0001740547
Urovant Sciences Ltd.
UROV
0001748297
Haag-Molkenteller Cornelia
C/O UROVANT SCIENCES, INC.
5151 CALIFORNIA AVENUE, SUITE 250
IRVINE
CA
92617
0
1
0
0
CMO of Urovant Sciences, Inc.
Common Shares
0
D
Stock Option (Right to Buy)
7.53
2028-05-20
Common Shares
146850
D
25% of the total shares underlying the option shall vest and become exercisable on April 9, 2019; the remaining shares vest in 12 equal quarterly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date.
Exhibit List - Exhibit 24.1 - Power of Attorney
/s/ John T. McKenna, Attorney-in-Fact
2018-09-26
EX-24.3_810845
2
poa.txt
POA DOCUMENT
UROVANT SCIENCES LTD.
POWER OF ATTORNEY
(For Executing Form ID and Forms 3, 4 and 5)
Know all by these presents, that the undersigned hereby constitutes and appoints
each of John McKenna and Alison Haggerty of Cooley LLP and Bryan Smith and
Christine Ocampo of Urovant Sciences, Inc., with full power of substitution,
signing individually, the undersigned's true and lawful attorneys-in fact and
agents to:
1. Prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission (the "SEC") Form ID,
Uniform Application for Access Codes to File on EDGAR, including amendments
thereto, and any other documents necessary or appropriate to obtain codes and
passwords enabling the undersigned to make electronic filings with the SEC of
reports required by Section 16(a) of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), or any rule or regulation thereunder;
2. Prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the SEC Forms 3, 4 and 5 (including amendments thereto and joint
filing agreements in connection therewith) in accordance with Section 16(a) of
the Exchange Act and the rules and regulations thereunder in the undersigned's
capacity as an officer, director or beneficial owner of more than 10% of a
registered class of securities of Urovant Sciences Ltd. (the "Company");
3. Do and perform any and all acts for and on behalf of the undersigned that may
be necessary or desirable to execute such Forms 3, 4, or 5, or Form ID
(including any amendments thereto) and timely file such forms with the SEC, and
any stock exchange, self-regulatory association or similar authority; and
4. Take any other action of any nature whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney in fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney in fact, or such attorney
in fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted. The
undersigned acknowledges that the foregoing attorneys-in-fact, and their
substitutes, in serving in such capacity at the request of the undersigned, are
not assuming (nor is the Company assuming) any of the undersigned's
responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact is no longer employed by Cooley LLP or
Urovant Sciences, Inc. or another subsidiary of the Company, as applicable.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.
Date: July 23, 2018
/s/ Cornelia Haag-Molkenteller
Cornelia Haag-Molkenteller, MD., Ph.D.